Both assets are poised to enter registrational studies under accelerated approval pathways, according to Jefferies. GSK to Stay Out of Obesity—but not GLP-1s At JPM25 on Monday, GSK Chief Scientific ...

The Congress party will move to its new headquarters, which has been inaugurated today, after 47 years of conducting its business out of 24 Akbar Road. The Type VII bungalow in the heart of ...

GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare Conference, the European healthcare giant noted there ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

Glenview village officials last month issued the death knell for one of the great corporate headquarters of the 20th century. The old Scott Foresman headquarters on Lake Avenue, which opened in ...

GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts-based ...

From left, Dude Perfect’s Cory Cotton, Cody Jones, Tyler Toney, Garrett Hilbert, and Coby Cotton, pose for a YouTube video on Thursday, March 7, 2024 at Dude Perfect headquarters in Frisco.

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

GSK fired the opening gun for the 2025 JP Morgan Healthcare Conference on Monday with a front-loaded acquisition agreement, moving to buy precision therapy specialist IDRx and its rare cancer drug ...